ObjectiveHealth, a pioneer in integrated specialty research, today announced a strategic investment from Vitruvian Partners, a renowned global growth equity firm.
– This strategic investment will fuel ObjectiveHealth’s expansion and its mission to revolutionize clinical research by seamlessly integrating trials into the practices of community-based physicians.
Transforming Clinical Trials, One Patient at a Time:
ObjectiveHealth stands out with its innovative approach. They act as a bridge between pharmaceutical companies and patients, seamlessly integrating clinical trials into the existing workflows of specialty physicians. This is achieved through:
- Proprietary AI technology: Leveraging patient electronic health record data and physician schedules, ObjectiveHealth’s AI efficiently identifies potential trial candidates, saving time and resources.
- Streamlined trial management: Their platform simplifies trial workflow, providing physicians with tools to manage the process effectively.
- Dedicated research coordinators: On-site coordinators ensure smooth trial execution and support both patients and physicians.
- Community-based centers-of-excellence: By embedding trials within existing practices, ObjectiveHealth creates centers of excellence in specialty care, benefiting both patients and the research community.
Vitruvian Partners Fuels Growth:
Vitruvian’s investment recognizes ObjectiveHealth’s potential to disrupt the clinical research landscape. This funding will enable the company to:
- Expand its network of partner practices: Reach a wider pool of patients and drive greater participation in vital clinical trials.
- Further develop its AI technology: Enhance patient matching capabilities and streamline trial management processes.
- Invest in research infrastructure: Strengthen its capabilities to conduct high-quality clinical research across diverse specialties.
